Researchers from the Institute of Science Tokyo and Osaka Medical and Pharmaceutical University said that they have developed a peptide that can bind to the spike proteins of SARS-CoV-2 to prevent COVID-19 infections.
The peptide, which is a short chain of amino acids, has shown effectiveness in experiments involving various coronavirus strains attempting to infect human cell lines and hamsters.
Researchers hope to conduct a physician-led clinical trial for possible preventive and therapeutic treatment.
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.